register

Medical

Gene therapy paving the way for novel glaucoma treatment

Health Industry Hub | November 9, 2020 |

Medical News: Australian researchers have used gene therapy to regenerate damaged optic nerve fibres in a discovery that could help treat glaucoma, one of the world’s leading causes of blindness.

The pre-clinical study, led by Professor Keith Martin from the Centre for Eye Research Australia and University of Melbourne and Dr Richard Eva, Dr Veselina Petrova and Professor James Fawcett from the John van Geest Centre for Brain Repair at the University of Cambridge, is published in Nature Communications.

Professor Martin says the findings bring hope of future treatments which could repair nerve damage which causes blindness in glaucoma and potentially even restore sight.

Around 300,000 Australians have glaucoma, a disease caused by progressive damage to the optic nerve which transfers visual information from the eye to the brain.

Conventional treatments focus on reducing eye pressure to prevent optic nerve damage, but they do not work for about 15% of patients and there is currently no way to repair damaged nerve cells.

The team tested whether a gene responsible for producing a protein known as protrudin could stimulate the regeneration of nerve cells and stop them from dying when they were injured.

They used a cell culture system to grow brain cells in the lab and then injured them using a laser before introducing a gene to increase the amount of protrudin in the cells, vastly increasing their ability to repair and regenerate.

Tests of eye and optic nerve cells found the protein enabled significant regeneration weeks after a crush injury to the optic nerve.

The research also demonstrated almost complete protection of nerve cells from a mouse retina growing in cell culture, a technique which would usually be expected to result in extensive cell death.

Professor Martin said the results are promising. “What we’ve seen is the strongest regeneration of any technique we’ve used before,’’ he said.

“In the past it seemed impossible we would be able to regenerate the optic nerve but this research shows the potential of gene therapy to do this.’’

The international team is continuing its collaboration in Melbourne and Cambridge. Professor Martin said next steps are to explore the ability of protrudin to protect and regenerate human retinal cells.


News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone […]

More


News & Trends - Pharmaceuticals

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Industry Hub | March 1, 2024 |

Pharma News: Mark Butler MP, Federal Minister for Health, and Senator Anne Ruston, Shadow Minister for Health, reflected on the […]

More


News & Trends - Pharmaceuticals

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Health Industry Hub | March 1, 2024 |

Pharma News: Gilead has applied to the Medical Services Advisory Committee (MSAC) for funding of its cutting-edge CAR T-cell therapy, […]

More


News & Trends - MedTech & Diagnostics

Should private insurers face scrutiny for soaring profits while patients foot the bill? MTAA, Private Healthcare Australia

Should private health insurers face scrutiny for soaring profits while patients foot the bill?

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: In a clash of interests, the Medical Technology Association of Australia (MTAA) has once again urged […]

More


This content is copyright protected. Please subscribe to gain access.